Vyant Bio, Inc. (VYNT) Stock Analysis
DELISTED 2023
What happened to Vyant Bio, Inc. (VYNT) stock?
Vyant Bio, Inc. (VYNT) no longer trades on public markets. It was delisted in December 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vyant Bio, Inc. (VYNT) trades at $0.194. Vyant Bio, Inc. is a biotechnology company focused on discovering drugs for complex neurodevelopmental and neurodegenerative disorders. Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for VYNT: VYNT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VYNT against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
VYNT: 1/2 scored disciplines lean bearish.
How is this calculated? →Vyant Bio, Inc. (VYNT) Healthcare & Pipeline Overview
Vyant Bio, Inc. is a biotechnology firm specializing in drug discovery for neurodevelopmental and neurodegenerative disorders. Utilizing a CNS drug discovery platform with human-derived organoid models and machine learning, Vyant Bio aims to identify treatments for rare genetic conditions like Rett Syndrome and Parkinson's disease, positioning itself in the competitive biotechnology landscape.
What Is the Investment Thesis for VYNT?
Vyant Bio presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on rare CNS genetic disorders and its innovative drug discovery platform offer potential for significant growth if clinical candidates prove successful. However, the company's negative profit margin of -3406.9% and gross margin of -51.4% indicate substantial financial challenges. Key value drivers include successful identification and development of clinical candidates for Rett Syndrome, CDKL5 deficiency disorders, and Parkinson's disease. Upcoming catalysts include advancements in their collaboration agreement for Parkinson's Disease and progress in clinical trials. Investors should carefully consider the risks associated with biotechnology investments, including regulatory hurdles, clinical trial failures, and the need for additional capital.
Based on FMP financials and quantitative analysis
VYNT Key Highlights
Vyant Bio operates in the high-growth biotechnology sector, focusing on neurodevelopmental and neurodegenerative disorders.
- The company's CNS drug discovery platform combines human-derived organoid models, scaled biology, and machine learning.
- Vyant Bio targets rare CNS genetic disorders, including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD), and familial Parkinson's disease (PD).
- The company has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease.
- Vyant Bio's financial performance shows a P/E ratio of -0.05, a Profit Margin of -3406.9%, and a Gross Margin of -51.4%.
Who Are VYNT's Competitors?
VYNT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
| UTHR United Therapeutics Corporation | $520.23 | -1.68% | $22.1B | 98 |
| NBIX Neurocrine Biosciences, Inc. | $153.42 | -1.37% | $15.4B | 93 |
| EXEL Exelixis, Inc. | $53.69 | -1.29% | $13.5B | 98 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VYNT's Key Strengths?
Proprietary CNS drug discovery platform.
- Focus on rare CNS genetic disorders.
- Human-derived organoid models of brain disease.
- Collaboration agreement for Parkinson's Disease.
What Are VYNT's Weaknesses?
Negative profit margin and gross margin.
- Small number of employees.
- Dependence on successful drug discovery and development.
- Limited revenue streams.
What Could Drive VYNT Stock Higher?
Progress in clinical trials for Rett Syndrome (Rett).
- Progress in clinical trials for CDKL5 deficiency disorders (CDD).
- Progress in clinical trials for familial Parkinson's disease (PD).
- Advancement of collaboration agreement for Parkinson's Disease.
- Expansion of CNS drug discovery platform.
What Are the Key Risks for VYNT?
Financial-distress signal — its Altman Z-Score of -11.95 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and clinical trial failures.
- Competition from larger pharmaceutical companies.
- Need for additional capital.
- Intellectual property risks.
- Dependence on successful drug discovery and development.
What Are the Growth Opportunities for VYNT?
- Expansion of CNS Drug Discovery Platform: Vyant Bio can expand its CNS drug discovery platform to include a broader range of neurodevelopmental and neurodegenerative disorders. The market for CNS therapeutics is substantial, projected to reach $158 billion by 2028. By leveraging its human-derived organoid models and machine learning capabilities, Vyant Bio can identify new clinical candidates and attract partnerships with larger pharmaceutical companies. Timeline: Ongoing, with continuous platform development and expansion.
- Advancement of Clinical Candidates: The successful advancement of clinical candidates for Rett Syndrome, CDKL5 deficiency disorders, and familial Parkinson's disease represents a significant growth opportunity. Each of these rare genetic disorders has a limited number of treatment options, creating a high unmet medical need. Positive clinical trial results could lead to accelerated regulatory approval and commercialization. Timeline: 2-5 years, depending on clinical trial progress.
- Strategic Collaborations and Partnerships: Vyant Bio can pursue strategic collaborations and partnerships with pharmaceutical companies and research institutions to accelerate drug discovery and development. Collaborations can provide access to additional funding, expertise, and resources. The company's existing collaboration agreement for Parkinson's Disease serves as a model for future partnerships. Timeline: Ongoing, with continuous efforts to establish new collaborations.
- Repurposing of Existing Drugs: Vyant Bio's focus on identifying repurposed small molecule clinical candidates offers a cost-effective and time-efficient approach to drug development. Repurposing existing drugs can reduce the time and cost associated with traditional drug development pathways. The company can leverage its CNS drug discovery platform to identify new uses for existing drugs in the treatment of rare CNS genetic disorders. Timeline: 1-3 years, depending on the availability of suitable drug candidates.
- Expansion into Personalized Medicine: Vyant Bio can expand its focus on personalized medicine by tailoring treatments to individual patients based on their genetic profiles and disease characteristics. The company's human-derived organoid models can be used to predict individual patient responses to different therapies. This approach can improve treatment outcomes and reduce the risk of adverse events. Timeline: 3-5 years, with the development of personalized medicine capabilities.
What Are VYNT's Competitive Advantages?
- Proprietary CNS drug discovery platform.
- Human-derived organoid models of brain disease.
- Expertise in scaled biology and machine learning.
- Focus on rare CNS genetic disorders with limited competition.
What Does VYNT Do?
Vyant Bio, Inc. is a biotechnology company dedicated to discovering and developing drugs for complex neurodevelopmental and neurodegenerative disorders. The company was founded with the goal of addressing unmet medical needs in the central nervous system (CNS) therapeutic area, particularly focusing on rare genetic disorders. Vyant Bio's core technology is its CNS drug discovery platform, which integrates human-derived organoid models of brain disease, scaled biology, and machine learning. This platform enables the company to model and study neurological disorders in a more physiologically relevant manner compared to traditional methods. Vyant Bio focuses on identifying both repurposed and novel small molecule clinical candidates. Their research is primarily targeted towards rare CNS genetic disorders, including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD), and familial Parkinson's disease (PD). The company has also established a collaboration agreement to discover drugs for the treatment of Parkinson's Disease, expanding its research and development efforts. Based in Cherry Hill, New Jersey, Vyant Bio operates with a small team, indicating a lean and focused approach to drug discovery and development within the competitive biotechnology sector.
What Products and Services Does VYNT Offer?
- Discovers drugs for complex neurodevelopmental disorders.
- Discovers drugs for complex neurodegenerative disorders.
- Utilizes a CNS drug discovery platform.
- Combines human-derived organoid models of brain disease.
- Employs scaled biology and machine learning.
- Identifies repurposed small molecule clinical candidates.
- Identifies novel small molecule clinical candidates.
- Focuses on rare CNS genetic disorders.
How Does VYNT Make Money?
- Drug discovery and development for CNS disorders.
- Collaboration agreements with pharmaceutical companies.
- Out-licensing of drug candidates.
- Potential for revenue generation through drug sales upon regulatory approval.
What Industry Does VYNT Operate In?
Vyant Bio operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The industry is driven by the increasing prevalence of diseases, technological advancements, and the demand for innovative therapies. Vyant Bio's focus on rare CNS genetic disorders positions it within a niche market with limited competition but also significant regulatory and clinical development challenges. Competitors include companies like BioLineRx (BLCM), Caladrius Biosciences (CLBS), Cytosorbents Corporation (CYTO), Implanta Medical (IMPL), and Nabriva Therapeutics (NBSE), each with their own therapeutic focus and technology platforms.
Who Are VYNT's Key Customers?
- Patients with Rett Syndrome (Rett).
- Patients with CDKL5 deficiency disorders (CDD).
- Patients with familial Parkinson's disease (PD).
- Pharmaceutical companies through collaboration agreements.
Company Profile
Vyant Bio, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cherry Hill, US. The company is led by CEO Andrew D.C. LaFrence CPA. VYNT has traded publicly since 2021.
Financial Health
Vyant Bio, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.95 places it in the distress zone, a signal of elevated financial risk.
VYNT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Vyant Bio's recent insider buying suggests those in the know see value, a potential signal for future growth. Think of it like when Elon bought Tesla shares in 2019, boosting investor confidence.
- Community sentiment seems to be shifting positively; more users are discussing potential applications of their drug discovery platform. This mirrors the early buzz around CRISPR technology.
- There's growing optimism about their central nervous system (CNS) pipeline, with hopes for breakthroughs in treating rare diseases. This is similar to the excitement surrounding Vertex's cystic fibrosis drugs.
- The market is increasingly recognizing the potential of personalized medicine, which aligns with Vyant Bio's focus. This trend resembles the increasing valuation of companies specializing in gene therapy.
Bear Case
- Recent community discussions highlight concerns about Vyant Bio's cash burn rate and potential need for future funding. This echoes worries about companies like Sorrento Therapeutics facing liquidity issues.
- Some investors are skeptical about the timeline for their drug development programs, citing regulatory hurdles. This mirrors the challenges faced by many biotech firms in getting FDA approval.
- There's a perception that Vyant Bio is heavily reliant on a few key assets, making them vulnerable to setbacks. This is similar to concerns about companies with limited product portfolios.
- Negative sentiment has surfaced regarding competition in the CNS space, with worries about larger players overshadowing Vyant Bio. This is comparable to smaller electric vehicle companies competing with Tesla.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VYNT Latest News
No recent news available for VYNT.
Leadership: Andrew D.C. LaFrence CPA
CEO
Andrew D.C. LaFrence is a Certified Public Accountant (CPA) and serves as the CEO of Vyant Bio, Inc. His background likely includes financial management and accounting expertise, which is crucial for guiding a biotechnology company through its early stages of development. Given the small team size of four employees, LaFrence likely plays a multifaceted role, overseeing both strategic direction and operational execution. His CPA credentials suggest a strong understanding of financial reporting and compliance, essential for attracting investors and managing resources effectively.
Track Record: Due to limited information, Andrew D.C. LaFrence's specific achievements and strategic decisions at Vyant Bio are not readily available. However, as CEO, he is responsible for guiding the company's drug discovery efforts, securing collaborations, and managing the company's financial resources. The success of Vyant Bio's clinical candidates and the establishment of strategic partnerships would be key milestones under his leadership.
Vyant Bio, Inc. Healthcare Stock: Key Questions Answered
What happened to Vyant Bio, Inc. (VYNT) stock?
Vyant Bio, Inc. (VYNT) no longer trades on public markets. It was delisted in December 2023. The figures below are historical and are not a current quote.
Can I still buy VYNT shares?
No. VYNT stopped trading on public markets in December 2023, so the shares are not available through a broker. Anything you see quoted for VYNT elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before VYNT stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Vyant Bio, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Vyant Bio, Inc. do?
Vyant Bio, Inc. is a biotechnology company focused on discovering and developing drugs for complex neurodevelopmental and neurodegenerative disorders. The company's core technology is its CNS drug discovery platform, which integrates human-derived organoid models of brain disease, scaled biology, and machine learning.
What are the main risks for VYNT?
Vyant Bio, Inc. faces several key risks inherent to the biotechnology industry. These include the potential for regulatory hurdles and clinical trial failures, which can significantly impact the company's ability to bring its drug candidates to market. Competition from larger pharmaceutical companies with greater resources and established market presence also poses a threat.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's specific achievements and strategic decisions.
- AI analysis is pending, which may provide additional insights.